UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Malignant pleural effusion of multiple myeloma: Prognostic factors and outcome

Leukemia & lymphoma, 2005-08, Vol.46 (8), p.1137-1142

2005

Volltextzugriff (PDF)

Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Journal of clinical oncology, 2018-03, Vol.36 (8), p.728-734

2018

Volltextzugriff (PDF)

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

The lancet oncology, 2010-01, Vol.11 (1), p.29-37

2010

Volltextzugriff (PDF)

Corporate Social Responsibility: Strategic Implications

Journal of management studies, 2006-01, Vol.43 (1), p.1-18

2006

Volltextzugriff (PDF)

Assessing the impact of organizational practices on the relative productivity of university technology transfer offices: An exploratory study

Research policy, 2003, Vol.32 (1), p.27-48

2003

Volltextzugriff (PDF)

Science parks and incubators: observations, synthesis and future research

Journal of business venturing, 2005-03, Vol.20 (2), p.165-182

2005

Volltextzugriff (PDF)

EE56 Cost-Effectiveness Analysis of Motixafortide on Top of G-CSF for Stem Cell Mobilization for Autologous Bone Marrow Transplantation in Patients with Multiple Myeloma

Value in health, 2022-07, Vol.25 (7), p.S346

2022

Volltextzugriff (PDF)

Frequency, Characteristics, and Reversibility of Peripheral Neuropathy During Treatment of Advanced Multiple Myeloma With Bortezomib

Journal of clinical oncology, 2006-07, Vol.24 (19), p.3113-3120

2006

Volltextzugriff (PDF)

Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results

British journal of haematology, 2018-03, Vol.180 (6), p.821-830

2018

Volltextzugriff (PDF)

Guidance for Use and dosing of Selinexor in Multiple Myeloma in 2021: Consensus From International Myeloma Foundation Expert Roundtable

Clinical lymphoma, myeloma and leukemia, 2022-07, Vol.22 (7), p.e526-e531

2022

Volltextzugriff (PDF)

Toward a model of the effective transfer of scientific knowledge from academicians to practitioners: qualitative evidence from the commercialization of university technologies

Journal of engineering and technology management, 2004-03, Vol.21 (1), p.115-142

2004

Volltextzugriff (PDF)

The Impact of Investment in IT on Economic Performance: Implications for Developing Countries

World development, 2005-05, Vol.33 (5), p.681-700

2005

Volltextzugriff (PDF)

Assessing the Impact of Management Buyouts on Economic Efficiency: Plant-Level Evidence from the United Kingdom

The review of economics and statistics, 2005-02, Vol.87 (1), p.148-153

2005

Volltextzugriff (PDF)

Assessing the impact of university science parks on research productivity: exploratory firm-level evidence from the United Kingdom

International journal of industrial organization, 2003-11, Vol.21 (9), p.1357-1369

2003

Volltextzugriff (PDF)

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor (NCT03158688)

BLOOD, 2019-11, Vol.134 (Supplement_2), p.LBA-6-LBA-6

2019

Volltextzugriff (PDF)

Toxic acute tubular necrosis following treatment with zoledronate (Zometa)

Kidney international, 2003-07, Vol.64 (1), p.281-289

2003

Volltextzugriff (PDF)

Phase I/II Study of Escalating Doses of Thalidomide in Conjunction with Bortezomib and High Dose Melphalan As a Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma

Blood, 2018-11, Vol.132 (Supplement 1), p.2154-2154

2018

Volltextzugriff (PDF)

Preferences and Priorities for Relapsed Multiple Myeloma Treatments Among Patients and Caregivers in the United States

Patient preference and adherence, 2022-03, Vol.16, p.573-585

2022

Volltextzugriff (PDF)

Science Parks and the Performance of New Technology-Based Firms: A Review of Recent U.K. Evidence and an Agenda for Future Research

Small business economics, 2003-03, Vol.20 (2), p.177-184

2003

Volltextzugriff (PDF)

University-based technology initiatives: Quantitative and qualitative evidence

Research policy, 2005, Vol.34 (3), p.253-257

2005

Volltextzugriff (PDF)

Universities and Fundamental Research: Reflections on the Growth of University–Industry Partnerships

Oxford review of economic policy, 2002-03, Vol.18 (1), p.10-21

2002

Volltextzugriff (PDF)

Population pharmacokinetics of pomalidomide in patients with relapsed or refractory multiple myeloma with various degrees of impaired renal function

Clinical pharmacology: advances and applications, 2017-01, Vol.9, p.133-145

2017

Volltextzugriff (PDF)

Role of NF-κB in the Rescue of Multiple Myeloma Cells From Glucocorticoid-Induced Apoptosis by Bcl-2

Blood, 1999-05, Vol.93 (9), p.3044-3052

1999

Volltextzugriff (PDF)

The Contributions and Disconnections Between Writing a Business Plan and The Start-up Process for Incubator Technology Entrepreneurs

Academic Entrepreneurship: Creating an Entrepreneurial Ecosystem, 2014, Vol.16, p.197-241

2014

Volltextzugriff (PDF)

Age Is Not a Prognostic Variable With Autotransplants for Multiple Myeloma

Blood, 1999-01, Vol.93 (1), p.51-54

1999

Volltextzugriff (PDF)

1 – 25 von 157

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(121)
Mit Volltextzugriff
(130)

Publikationsform

Sprache

Englisch
(157)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Malignant pleural effusion of multiple myeloma: Prognostic factors and outcome

Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

Corporate Social Responsibility: Strategic Implications

Assessing the impact of organizational practices on the relative productivity of university technology transfer offices: An exploratory study

Science parks and incubators: observations, synthesis and future research

EE56 Cost-Effectiveness Analysis of Motixafortide on Top of G-CSF for Stem Cell Mobilization for Autologous Bone Marrow Transplantation in Patients with Multiple Myeloma

Frequency, Characteristics, and Reversibility of Peripheral Neuropathy During Treatment of Advanced Multiple Myeloma With Bortezomib

Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results

Guidance for Use and dosing of Selinexor in Multiple Myeloma in 2021: Consensus From International Myeloma Foundation Expert Roundtable

Toward a model of the effective transfer of scientific knowledge from academicians to practitioners: qualitative evidence from the commercialization of university technologies

The Impact of Investment in IT on Economic Performance: Implications for Developing Countries

Assessing the Impact of Management Buyouts on Economic Efficiency: Plant-Level Evidence from the United Kingdom

Assessing the impact of university science parks on research productivity: exploratory firm-level evidence from the United Kingdom

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor (NCT03158688)

Toxic acute tubular necrosis following treatment with zoledronate (Zometa)

Phase I/II Study of Escalating Doses of Thalidomide in Conjunction with Bortezomib and High Dose Melphalan As a Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma

Preferences and Priorities for Relapsed Multiple Myeloma Treatments Among Patients and Caregivers in the United States

Science Parks and the Performance of New Technology-Based Firms: A Review of Recent U.K. Evidence and an Agenda for Future Research

University-based technology initiatives: Quantitative and qualitative evidence

Universities and Fundamental Research: Reflections on the Growth of University–Industry Partnerships

Population pharmacokinetics of pomalidomide in patients with relapsed or refractory multiple myeloma with various degrees of impaired renal function

Role of NF-κB in the Rescue of Multiple Myeloma Cells From Glucocorticoid-Induced Apoptosis by Bcl-2

The Contributions and Disconnections Between Writing a Business Plan and The Start-up Process for Incubator Technology Entrepreneurs

Age Is Not a Prognostic Variable With Autotransplants for Multiple Myeloma

Suchergebnisse filtern